GoodRx Holdings, Inc. - 10-Q Summary (Q2 2025)
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 2025. GoodRx operates a digital healthcare platform in the U.S., offering prescription price comparison, savings codes, subscription programs, and pharmaceutical manufacturer solutions. The company reported its second consecutive quarter of profitability, though growth was tempered by significant headwinds in the retail pharmacy landscape.
Key Financial Metrics
| Metric | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Revenue | $203.1 million | $200.6 million | $406.0 million | $398.5 million |
| Net Income | $12.8 million | $6.7 million | $23.9 million | $5.7 million |
| Net Income Margin | 6.3% | 3.3% | 5.9% | 1.4% |
| Adjusted EBITDA | $69.4 million | $65.4 million | $139.2 million | $128.2 million |
| Adjusted EBITDA Margin | 34.2% | 32.6% | 34.3% | 32.2% |
| Cash & Equivalents | $281.3 million | $448.3 million (Dec '24) | N/A | |
| Debt (Net) | $490.0 million | $491.7 million (Dec '24) | N/A | |
| Operating Cash Flow (YTD) | $59.0 million | $52.3 million | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 1% QoQ and 2% YoY. Growth was driven by a 32% increase in Pharma Manufacturer Solutions revenue, which offset declines in Prescription Transactions (-3%) and Subscription revenue (-7%).
- Profitability: Net income more than doubled YoY ($12.8M vs $6.7M) due to improved operating leverage and lower interest expenses.
- Consumer Metrics: Monthly Active Consumers (MAC) declined 14% YoY to 5.7 million, attributed to retail pharmacy store closures and volume reductions in integrated savings programs.
- Acquisition: Completed the acquisition of VCRx for $30.0 million in cash in January 2025 to expand consumer reach.
- Stock Repurchases: Repurchased 10.2 million shares in Q2 2025 for $46.4 million. Total repurchases YTD were $145.9 million.
Outlook, Risks, and Management Commentary
- Headwinds: Management cites the bankruptcy of Rite Aid and subsequent store closures as a primary driver of reduced claims volume. PBMs removing Rite Aid from networks has caused an immediate cessation in associated claims.
- Revenue Impact: The company estimates a negative impact of $35.0 to $40.0 million on prescription transactions revenue for the full year 2025 due to these external factors.
- Strategic Initiatives: Launched a condition-specific subscription program for erectile dysfunction in Q2 2025, with plans to expand to other conditions later in the year.
- Legal Contingencies: A $25.0 million legal settlement regarding consumer privacy class actions is accrued but pending final court approval. The company is also defending against securities class actions and state-level litigation regarding discount card compliance.
- Tax Legislation: The "One Big Beautiful Bill Act" (OBBBA) was enacted in July 2025; impacts on financial statements will be recognized in Q3 2025.
Investor Verification Checklist
- Legal Settlement Status: Verify the final court approval status of the $25.0 million consumer privacy settlement and potential for additional indemnification costs.
- Retail Partner Exposure: Assess the long-term impact of Rite Aid's bankruptcy and the specific volume reduction in the integrated savings program mentioned by management.
- Debt Covenants: Confirm continued compliance with the First Lien Net Leverage Ratio covenant, especially given the $490 million debt load and reduced cash flow from operations.
- Subscription Churn: Monitor the trend of subscription plans (down to 668k from 696k YoY) and the success of the new condition-specific subscription launch.
- Capital Allocation: Review the remaining $143.0 million available under the stock repurchase program and the company's commitment to returning capital amidst operational headwinds.